# US 2024/0199762 A1 · Anti-fibroblast activation protein antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199762 A1
- Document ID: US20240199762A1
- Status: Published application
- Kind: A1
- Application number: 18/555,189
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Assignees: Philogen S.P.A.
- Applicants: Philogen S.P.A
- Inventors: Roberto DE LUCA; Lisa NADAL; Frederik PEISSERT
- Web page: https://patentgrep.com/patent/US20240199762A1

## CPC

- C07K 16/40: against enzymes
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 51/1075: {the antibody being against an enzyme}
- A61P 35/00: Antineoplastic agents
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/7155: {for interleukins [IL]}
- C12Y 304/14005: Dipeptidyl-peptidase IV (3.4.14.5)
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The application relates to the diagnosis and treatment of diseases, including cancer, autoimmune diseases and inflammatory disorders. The invention provides, and involves the use of, antibody molecules that bind fibroblast activation protein (FAP) from humans, sheep, pigs and domestic dogs. The antibody molecules may be conjugated to a pro-inflammatory agent, an anti-inflammatory agent, a biocidal molecule, a cytotoxic molecule, or a radioisotope.

## Claims

### Claim 1

An antibody molecule that binds human, canine, ovine and porcine fibroblast activation protein (FAP), wherein the antibody molecule comprises a VH domain comprising a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, and a VL domain comprising a set of complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein:
the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs 3, 4 and 5, respectively, and
the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs 6, 7 and 8, respectively.

### Claim 2 (depends on 1)

An antibody molecule according to claim 1, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 9 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 10.

### Claim 3 (depends on 1)

An antibody molecule according to claim 1, wherein the antibody molecule comprises the heavy chain amino acid sequence set forth in SEQ ID NO: 13 or 74, and the light chain amino acid sequence set forth in SEQ ID NO: 14.

### Claim 4 (depends on 1)

The antibody molecule according to claim 1, wherein the antibody molecule comprises or consists of: a single chain Fv (scFv), a small immunoprotein (SIP), a diabody, a single-chain diabody.

### Claim 5 (depends on 1)

A conjugate comprising an antibody molecule according to claim 1 and a pro-inflammatory agent, an anti-inflammatory agent, a biocidal molecule, a cytotoxic molecule, or a radioisotope.

### Claim 6 (depends on 5)

A conjugate according to claim 5, wherein the pro-inflammatory agent, or anti-inflammatory agent, is a cytokine.

### Claim 7 (depends on 6)

A conjugate according to claim 6, wherein the antibody molecule is a single-chain diabody and is conjugated at its N-terminus to IL12, and wherein the conjugate optionally comprises the sequence set forth in SEQ ID NO: 41.

### Claim 8 (depends on 6)

A conjugate according to claim 6, wherein the antibody molecule is an IgG4 molecule and the C-terminus of the heavy chain is conjugated to interferon gamma, or a variant thereof, and wherein the conjugate optionally comprises the light and heavy chain sequences set forth in SEQ ID NOs 14 and 37, respectively.

### Claim 9 (depends on 6)

A conjugate according to claim 6, wherein the antibody molecule is an scFv and is conjugated at its N-terminus to interleukin-2, and at its C-terminus to tumor necrosis factor alpha (TNFα) or a variant thereof, and wherein the conjugate optionally has the sequence set forth in SEQ ID NO: 31 or 82.

### Claim 10 (depends on 6)

A conjugate according to claim 6, wherein the antibody molecule is a diabody (db) and is conjugated at its C-terminus to interleukin-2, and wherein the conjugate optionally has the sequence set forth in SEQ ID NO: 76 to interleukin-2, and wherein the conjugate optionally has the sequence set forth in SEQ ID NO: 76.

### Claim 11 (depends on 6)

A conjugate according to claim 6, wherein the antibody molecule is a single-chain diabody (scDb) and is conjugated at its C-terminus the sushi-domain of IL15 Receptor alpha (SD), and interleukin-15 is conjugated to the C-terminus of the sushi domain, and wherein the conjugate optionally has the sequence set forth in SEO ID NO: 79.

### Claim 12 (depends on 1)

A method of treating an inflammatory disorder, autoimmune disease, or cancer in a patient, comprising administering a therapeutically effective amount of the antibody molecule of claim 1 to the patient.

### Claim 13 (depends on 7)

A method of treating an inflammatory disorder, autoimmune disease, or cancer in a patient, comprising administering a therapeutically effective amount of the conjugate of claim 7 to the patient, wherein the method further comprises administering a Janus kinase (JAK) inhibitor to the patient.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the JAK inhibitor is selected from the group consisting of: ruxolitinib, baricitinib, tofacitinib, fedratinib, momelotinib, pacritinib, fligotinib, upadacitinib, itacitinib, decernotinib, peficitinib, deucravacitinib, abrocitinib, NDI-031301, and ritlecitinib.

### Claim 15

(canceled)

### Claim 16 (depends on 5)

A method of cancer in a patient, comprising administering a therapeutically effective amount of the conjugate of claim 5 to the patient, wherein the method further comprises administering an immunomodulatory agent to the patient.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the immunomodulatory agent is selected from the group consisting of: an anti-PD-1 antibody, anti-PD-L1 antibody, anti-LAG-3 antibody, anti-TIGIT antibody, and anti-TIM-3 antibody.

### Claim 18

(canceled)

### Claim 19 (depends on 13)

The method according to any one of claims 13, wherein the conjugate comprises, or consist of, the sequence set forth in SEQ ID NO: 41.

### Claim 20 (depends on 1)

A nucleic acid molecule or expression vector encoding an antibody molecule or conjugate according to claim 1.

### Claim 21 (depends on 20)

A host cell comprising the nucleic acid or vector of claim 20.

### Claim 22 (depends on 1, 21)

A method of producing an antibody molecule or conjugate according to claim 1, comprising culturing the host cell of claim 21 under conditions for expression of the antibody molecule or conjugate, and optionally further isolating and/or purifying the antibody molecule or conjugate following expression.
